KORTHOS / ECOSYSTEM / PRODUCT

UGO

About

About UGO

UGO uses multiple sensors to detect the wearer’s gait and adjust powered movement to their current state. A touchscreen allows walking speed and stride to be changed for a training session. The system supports repeated assisted stepping as part of an individual walking-rehabilitation programme.

RoboCT offers UGO for home use following an assessment of the prospective user. The specified fitting range covers people 1.5–1.9 metres tall and weighing up to 100 kilograms. This assessment and adjustment process is central to matching the powered exoskeleton to the wearer. Walking speed and stride settings can then be adjusted for the training session.

21 OCT 2026

ugo raises ¥1B in debt funding for Nova semi-humanoid production

18 SEPT 2026

Humanoid production and supply chain — 10–18 September 2026

16 SEPT 2026

ugo unveils Japan-built Nova semi-humanoid ahead of 2027 production

Timeline

  • RoboCT exoskeleton range enters Northern Malaysia evaluations

    2026-09-14 - Demonstration - The regional programme expands Robotimize’s RoboCT activity beyond the Klang Valley and presents multiple devices for adult, paediatric and elderly mobility needs. Clinicians and caregivers are evaluating how the systems fit existing rehabilitation programmes and care pathways. The activity is an introduction and evaluation programme; product use remains subject to local clinical requirements and applicable regulatory approvals.

    Source

Context

Market context

Lower-limb rehabilitation exoskeleton for gait training and neurological recovery in clinical settings.

  • Target environment: Clinical, rehabilitation, assistive and therapy environments where robot hardware supports patient or operator workflows.
  • Workflow context: Assisted movement, therapy, rehabilitation support, clinical workflow aid and supervised human interaction.
  • Customer context: Hospitals, clinics, rehabilitation centers, therapists and assistive-technology users.
  • Deployment model: Commercial or available product positioned for customer use, integration or developer adoption.
  • Commercial maturity: Publicly presented as commercial or available, with maturity depending on deployment scale and support coverage.
  • Adoption constraints: Adoption depends on clinical validation, safety, patient fit, reimbursement, workflow integration and support.
  • Market position: UGO sits in the healthcare robotics lane, where safety and workflow fit matter as much as hardware capability.
  • Adjacent products: EksoNR, ReWalk, Wandercraft Atalante, G-Gaiter

Comparable Systems